News Room

Investor Announcement, Huntington's Disease

Prana receives $6.8 million R&D Tax Incentive Refund

Prana Biotechnology Limited has today announced that it has received a $6.8 million cash refund under the Australian Government’s R&D Tax Incentive Scheme.

The refund relates to the cost of eligible research and development activities conducted during the 2014 financial year. These funds will be used to further Prana’s development of PBT2 for the treatment of Huntington’s Disease.